Biogen Inc. Q3 2025 Earnings Recap

BIIB Q3 2025 October 31, 2025

Biogen reported a robust third quarter in 2025, highlighted by a 67% growth in launch product revenues and strong demand for LEQEMBI and ZURZUVAE, positioning the company favorably within the neurological and autoimmune markets.

Earnings Per Share Beat

$4.81 vs $3.88 est.

+24.0% surprise

Revenue Beat

2454800000 vs 2340021835 est.

+4.9% surprise

Market Reaction

1-Day -1.83%

5-Day +0.8%

30-Day +17.16%

Key Takeaways

Launch products drove significant revenue growth, with LEQEMBI sales reaching $121 million.
ZURZUVAE experienced a remarkable 150% increase in year-over-year revenue, reshaping perceptions of postpartum depression.
Biogen is advancing a strong pipeline, with 10 Phase III programs, including promising candidates for lupus and other autoimmune diseases.
The acquisition of Alcyone Therapeutics enhances Biogen's capabilities in delivering innovative therapies via ASO administration.
Strong talent acquisition indicates confidence in Biogen's commercial prospects and new product pipeline.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit BIIB on AllInvestView.